{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:23Z","timestamp":1793191043392,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40121-025-01185-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:33:40Z","timestamp":1751362420000},"page":"1973-1987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2\/3 Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05997290","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Oyeniyi","family":"Diya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2974-5302","authenticated-orcid":false,"given":"Juleen","family":"Gayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine S.","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishva","family":"Bangad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Mogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"T\u00fcreci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u01e7ur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvon","family":"Modjarrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kitchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1185_CR1","unstructured":"World Health Organization. COVID-19 advice for the public: getting vaccinated. WHO. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice. Accessed 24 Jan 2025."},{"key":"1185_CR2","first-page":"1817","volume":"329","author":"E Harris","year":"2023","unstructured":"Harris E. WHO declares end of COVID-19 global health emergency. JAMA. 2023;329:1817.","journal-title":"JAMA"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361\u201379.","journal-title":"Nat Rev Microbiol"},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12879-024-09282-4","volume":"24","author":"TP Le","year":"2024","unstructured":"Le TP, Abell I, Conway E, et al. Modelling the impact of hybrid immunity on future COVID-19 epidemic waves. BMC Infect Dis. 2024;24:407.","journal-title":"BMC Infect Dis"},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"2212568","DOI":"10.1080\/21645515.2023.2212568","volume":"19","author":"A Sarkar","year":"2023","unstructured":"Sarkar A, Omar S, Alshareef A, et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother. 2023;19:2212568.","journal-title":"Hum Vaccin Immunother"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7:1161\u201379.","journal-title":"Nat Microbiol"},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","volume":"637","author":"F Jian","year":"2025","unstructured":"Jian F, Wang J, Yisimayi A, et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature. 2025;637:921\u20139.","journal-title":"Nature"},{"key":"1185_CR8","unstructured":"Centers for Disease Control and Prevention. COVID data tracker: variant proportions. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions. Accessed 24 Jan 2025."},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595:572\u20137.","journal-title":"Nature"},{"key":"1185_CR10","unstructured":"US Food and Drug Administration. COMIRNATY\u00ae (COVID-19 Vaccine, mRNA) package insert. https:\/\/www.fda.gov\/vaccines-blood-biologics\/comirnaty. Accessed 26 Nov 2024."},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","volume":"386","author":"YM Bar-On","year":"2022","unstructured":"Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386:1712\u201320.","journal-title":"N Engl J Med"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMc2210093","volume":"387","author":"S Collie","year":"2022","unstructured":"Collie S, Nayager J, Bamford L, et al. Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa. N Engl J Med. 2022;387:1332\u20133.","journal-title":"N Engl J Med"},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"2315659","DOI":"10.1080\/21645515.2024.2315659","volume":"20","author":"F van den Ouweland","year":"2024","unstructured":"van den Ouweland F, Charpentier N, T\u00fcreci \u00d6, et al. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: development, post-marketing surveillance, and real-world data. Hum Vaccin Immunother. 2024;20:2315659.","journal-title":"Hum Vaccin Immunother"},{"key":"1185_CR14","unstructured":"US Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in fall 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024. Accessed 18 Sept 2024."},{"key":"1185_CR15","unstructured":"European Medicine Agency. Authorised COVID-19 vaccines. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines#covid-19-vaccines-strains-use-and-age-ranges-14491. Accessed 24 Jan 2025."},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury DS, Docken SS, Subbarao K, et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat Med. 2023;29:574\u20138.","journal-title":"Nat Med"},{"key":"1185_CR17","doi-asserted-by":"crossref","unstructured":"Appaneal HJ, Lopes VV, Puzniak L, et al. Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System. medRxiv. 2024:2024.12.26.24319566.","DOI":"10.1101\/2024.12.26.24319566"},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/vaccines12020118","volume":"12","author":"J Gayed","year":"2024","unstructured":"Gayed J, Diya O, Lowry FS, et al. Safety and immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 years old: a phase 2\/3 trial. Vaccines (Basel). 2024;12:118.","journal-title":"Vaccines (Basel)."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/vaccines12070734","volume":"12","author":"J Gayed","year":"2024","unstructured":"Gayed J, Bangad V, Xu X, et al. Immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine against XBB.1.5, BA.2.86, and JN.1 sublineages: a phase 2\/3 trial. Vaccines (Basel). 2024;12:734.","journal-title":"Vaccines (Basel)."},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"126869","DOI":"10.1016\/j.vaccine.2025.126869","volume":"52","author":"O Diya","year":"2025","unstructured":"Diya O, Gayed J, Lowry FS, et al. A phase 2\/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults \u226518 years old. Vaccine. 2025;52:126869.","journal-title":"Vaccine"},{"key":"1185_CR21","doi-asserted-by":"crossref","unstructured":"Chen W, Tompkins KR, Windsor IW, et al. Immunologic and biophysical features of the BNT162b2 JN.1- and KP.2-adapted COVID-19 vaccines. bioRxiv. 2024:2024.11.04.621927.","DOI":"10.1101\/2024.11.04.621927"},{"key":"1185_CR22","doi-asserted-by":"crossref","unstructured":"Rudolph AE, Khan FL, Sun X, et al. Receipt of BNT162b2 KP.2 vaccine and COVID-19 CVS minuteclinic visits in US adults. medRxiv. 2025:2025.01.15.24319342.","DOI":"10.1101\/2025.01.15.24319342"},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/vaccines13010061","volume":"13","author":"CW Hou","year":"2025","unstructured":"Hou CW, Williams S, Boyle V, et al. Tracking immunity: an increased number of COVID-19 boosters increases the longevity of anti-RBD and anti-RBD-neutralizing antibodies. Vaccines (Basel). 2025;13:61.","journal-title":"Vaccines (Basel)"},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa2213082","volume":"388","author":"P Winokur","year":"2023","unstructured":"Winokur P, Gayed J, Fitz-Patrick D, et al. Bivalent Omicron BA.1-adapted BNT162b2 booster in adults older than 55 years. N Engl J Med. 2023;388:214\u201327.","journal-title":"N Engl J Med"},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/cid\/ciad718","volume":"78","author":"L Usdan","year":"2024","unstructured":"Usdan L, Patel S, Rodriguez H, et al. A bivalent Omicron-BA.4\/BA.5-adapted BNT162b2 booster in \u226512-year-olds. Clin Infect Dis. 2024;78:1194\u2013203.","journal-title":"Clin Infect Dis"},{"key":"1185_CR27","unstructured":"US Food and Drug Administration. FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. Accessed 1 Oct 2024."},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41541-024-01013-9","volume":"9","author":"K Modjarrad","year":"2024","unstructured":"Modjarrad K, Che Y, Chen W, et al. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine. NPJ Vaccines. 2024;9:229.","journal-title":"NPJ Vaccines."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01185-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:11:11Z","timestamp":1757203871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01185-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01185-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Federico Mensa, \u00d6zlem T\u00fcreci, and U\u01e7ur \u015eahin are BioNTech employees and may hold stock or stock options. \u00d6zlem T\u00fcreci, U\u01e7ur \u015eahin, Kena A. Swanson, and Kayvon Modjarrad report holding an interest in a patent relevant to this manuscript. Jing Zou, Xuping Xie, and Yanping Hu have received funding from Pfizer. Oyeniyi Diya is no longer an employee at Pfizer Ltd. All other authors (Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Annaliesa S. Anderson, Alejandra Gurtman and Nicholas Kitchin) are Pfizer employees and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study protocol was approved by the WCG Central institutional review board (approval number: 20233321; Princeton, NJ, USA), which was utilized by each study site. This substudy was conducted according to the protocol and consensus ethical principles derived from international guidelines (i.e., Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines), applicable good clinical practice guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and other relevant laws and regulations. All participants were required to provide a signed statement of informed consent before study-specific procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}